S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   3,349.16 (+0.64%)
DOW   27,386.98 (+0.68%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
Log in

LON:NIPTPremaitha Health Share Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.57 million shs
Average Volume395,406 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Premaitha Health PLC, a molecular diagnostic company, develops tests for non-invasive prenatal screening and other applications in the United Kingdom and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal screening test for pregnant women to estimate Down's syndrome, Edward's syndrome, and Patau's syndrome. The IONA test is a diagnostic system that enables clinical laboratory customers to perform the test in their own facilities. The company is headquartered in Manchester, the United Kingdom.
Read More
Premaitha Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-161-6676865

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive NIPT News and Ratings via Email

Sign-up to receive the latest news and ratings for NIPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Premaitha Health (LON:NIPT) Frequently Asked Questions

How were Premaitha Health's earnings last quarter?

Premaitha Health PLC (LON:NIPT) announced its earnings results on Friday, December, 29th. The company reported ($2.00) earnings per share (EPS) for the quarter. The business had revenue of $2.71 million for the quarter.
View Premaitha Health's earnings history
.

Has Premaitha Health been receiving favorable news coverage?

Headlines about NIPT stock have been trending extremely negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Premaitha Health earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Premaitha Health
.

Who are some of Premaitha Health's key competitors?

Some companies that are related to Premaitha Health include VolitionRX (VNRX), Spectral Medical (EDT), ANGLE (AGL), Proteome Sciences (PRM) and DiaSorin (DIA).
View all competitors
.

What other stocks do shareholders of Premaitha Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Premaitha Health investors own include IQE (IQE), Avanti Communications Group (AVN), Chesapeake Utilities (CPK), Plethora Solutions (PLE), Vedanta Resources (VED), Mitie Group (MTO), Scancell (SCLP), Sirius Minerals (SXX), Advanced Micro Devices (AMD) and Aviva (AV).

Who are Premaitha Health's key executives?

Premaitha Health's management team includes the following people:
  • Dr. Stephen Little, Exec. Vice Chairman (Age 61)
  • Mr. Barry Hextall, CFO, Sec. & Exec. Director
  • Mr. Peter Collins, Chief Bus. Officer & Exec. Director (Age 59)
  • Mr. Lyn Fafydd Rees, CEO & Director (Age 45)
  • Dr. Chia-Han Chan, Chief Scientific Officer & Director (Age 42)

What is Premaitha Health's stock symbol?

Premaitha Health trades on the London Stock Exchange (LON) under the ticker symbol "NIPT."

How do I buy shares of Premaitha Health?

Shares of NIPT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Premaitha Health's official website?

The official website for Premaitha Health is www.premaitha.com.

How can I contact Premaitha Health?

Premaitha Health's mailing address is Rutherford House, 40 Pencroft Way, MANCHESTER, M15 6SZ, United Kingdom. The company can be reached via phone at +44-161-6676865.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.